Inovio Pharmaceuticals, Inc.
http://www.inovio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inovio Pharmaceuticals, Inc.
Three Chinese Biotechs Bag Late-Stage VC/PE Funding In February
Evopoint, I-Mab Biopharma (Hangzhou) and MAXVAX extended their funding with series E and C rounds, respectively, in February, amid signs that biotech investor sentiment in China may be recovering.
Apotex, Heritage, Breckenridge US Price-Fixing Settlements Could Top $50m
Direct purchasers of drugs from a trio of generics manufacturers in the US say they will receive payments that are fair and reasonable, under settled agreements that have been put before a judge in Pennsylvania.
Watch Out GSK! China’s Homegrown Shingles Vaccine Set To Soar
Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.
Stock Watch: Fewer Acquisitions Leave Many Behind
The biotech sector is so diverse that for every acquisition there will be at least one second-best. Even after years of independence following a drug approval, investors keep hoping that their pharmaceutical Prince Charming will arrive.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Bioject Medical Technologies
- Inovio Biomedical
- VGX Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice